The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: Involvement of P2Y 1 and P2Y12 receptors

Blood

Volumn 103, Issue 7, 2004, Pages 2585-2592

  Haserück, Nadine ^b   Erl, Wolfgang ^b   Pandey, Dharmendra ^b   Tigyi, Gabor ^b   Ohlmann, Philippe ^b   Ravanat, Catherine ^b   Gachet, Christian ^b   Siess, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LYSOPHOSPHATIDIC ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL INTERACTION; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 1642400249     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1127     Document Type: Article

References (41)

1. Siess W, Zangl KJ, Essler M, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 1999;96:6931-6936.
2. Sevanian A, Bittolo BG, Cazzolato G, et al. LDL is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res. 1997;38:419-428.
3. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998;98:1487-1494.
4. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549-1554.
5. Zeller JA, Tschoepe D, Kessler C. Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost. 1999;81:373-377.
6. Fateh-Moghadam S, Bocksch W, Ruf A, et al. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy. Circulation. 2000;102:890-897.
7. Maschberger P, Bauer M, Baumann-Siemons J, et al. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. J Biol Chem. 2000;275:19159-19166.
8. Retzer M, Essler M. Lysophosphatidic acid-induced platelet shape change proceeds via Rho/Rho kinase-mediated myosin light-chain and moesin phosphorylation. Cell Signal. 2000;12:645-648.
9. Retzer M, Siess W, Essier M. Mildly oxidised low density lipoprotein induces platelet shape change via Rho-kinase-dependent phosphorylation of myosin light chain and moesin. FEBS Lett. 2000;466:70-74.
10. Schumacher KA, Classen HG, Spath M. Platelet aggregation evoked in vitro and in vivo by phosphatidic acids and lysoderivatives: identity with substances in aged serum (DAS). Thromb Haemost. 1979;42:631-640.
11. Tokumura A, Fukuzawa K, Isobe J, Tsukatani H. Lysophosphatidic acid-induced aggregation of human and feline platelets: structure-activity relationship. Biochem Biophys Res Commun. 1981;99:391-398.
12. Haserūck N, Rother E, Corrinth C, Siess W. Comparison of platelet shape change and aggregation induced by lysophosphatidic acid and mildly oxidised LDL in platelet-rich plasma and in washed platelets [abstract]. Platelets. 2000;11:344.
13. Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001;38:1002-1006.
14. Yokoyama K, Baker DL, Virag T, et al. Stereochemical properties of lysophosphatidic acid receptor activation and metabolism. Biochim Biophys Acta. 2002;1582:295-308.
15. Baurand A, Raboisson P, Freund M, et al. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol. 2001;412:213-221.
16. Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JR. Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost. 1982;48:327-329.
17. Ruf A, Patscheke H. Flow cytometric detection of activated platelets: comparison of determining shape change, fibrinogen binding, and P-selectin expression. Semin Thromb Hemost. 1995;21:146-151.
18. Siess W, Roth P, Weber PC. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation. Thromb Haemost. 1981;45:204-207.
19. Gachet C, Cattaneo M, Ohlmann P, et al. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol. 1995;91:434-444.
20. Ohlmann P, Eckly A, Freund M, Cazenave JP, Offermanns S, Gachet C. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood. 2000;96:2134-2139.
21. Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis. 1994;5:121-131.
22. Rother E, Brandl R, Baker DL, et al. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation. 2003;108:741-747.
23. Baurand A, Eckly A, Bari N, et al. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost. 2000;84:484-491.
24. Gachet C. Platelet activation by ADP: the role of ADP antagonists. Ann Med. 2000;32(suppl 1):1520.
25. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110:925-934.
26. Siess W. Molecular mechanisms of platelet activation. Physiol Rev. 1989;69:58-178.
27. Siess W, Lapetina EG. Platelet aggregation induced by alpha 2-adrenoceptor and protein kinase C activation. A novel synergism. Biochem J. 1989;263:377-385.
28. 2+ ionophore A23187 synergistically induce platelet aggregation without protein kinase C activation. FEBS Lett. 1989;243:275-279.
29. Siess W. Multiple signal-transduction pathways synergize in platelet activation. News Physiol Sci. 1991;6:51-56.
30. Nieswandt B, Schulte V, Zywietz A, Gratacap MP, Offermanns S. Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin alpha Ilbbeta 3 activation in platelets. J Biol Chem. 2002;277:39493-39498.
31. Dorsam RT, Kim S, Jin J, Kunapuli SP. Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem. 2002;277:47588-47595.
32. Quinton TM, Kim S, Dangelmaier C, et al. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem J 2002;368:535-543.
33. Bauer M, Retzer M, Wilde JI, et al. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood. 1999;94:1665-1672.
34. Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta. 1989;1001:282-285.
35. Baker DL, Desiderio DM, Miller DD, Tolley B, Tigyi GJ. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal Biochem. 2001;292:287-295.
36. 2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost. 1989;62:968-976.
37. Billah MM, Lapetina EG, Cuatrecasas P, Phospholipase A2 activity specific for phosphatidic acid. A possible mechanism for the production of arachidonic acid in platelets. J Biol Chem. 1981;256:5399-5403.
38. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533-1537.
39. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A. 1994;91:8767-8771.
40. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97:1525-1534.
41. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990;65:168-172.